TN2009000049A1 - A pyrrolopyrazin as syk-kinase inhibitor - Google Patents

A pyrrolopyrazin as syk-kinase inhibitor

Info

Publication number: TN2009000049A1
Authority: TN; Tunisia
Prior art keywords: pyrrolopyrazin; syk; kinase inhibitor; prodrugs; compound
Prior art date: 2006-09-11

Application number

TN2009000049A

Other languages

English (en)

Inventor

Elizabeth M Allen

Kin T Yu

Timothy A Gillespy

A Zilberstein

Paul Eynott

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-11

Filing date

2009-02-17

Publication date

2010-08-19

2009-02-17 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2010-08-19 Publication of TN2009000049A1 publication Critical patent/TN2009000049A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Otolaryngology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

TN2009000049A 2006-09-11 2009-02-17 A pyrrolopyrazin as syk-kinase inhibitor TN2009000049A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82516806P	2006-09-11	2006-09-11
PCT/US2007/078103 WO2008033798A2 (fr)	2006-09-11	2007-09-11	Inhibiteur de kinases

Publications (1)

Publication Number	Publication Date
TN2009000049A1 true TN2009000049A1 (en)	2010-08-19

Family

ID=39032357

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
TN2009000049A TN2009000049A1 (en)	2006-09-11	2009-02-17	A pyrrolopyrazin as syk-kinase inhibitor
TN2009000050A TN2009000050A1 (en)	2006-09-11	2009-02-17	Production method of methane gas from olive mill waste

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
TN2009000050A TN2009000050A1 (en)	2006-09-11	2009-02-17	Production method of methane gas from olive mill waste

Country Status (32)

Country	Link
US (2)	US8658649B2 (fr)
EP (1)	EP2094708B1 (fr)
JP (1)	JP5161237B2 (fr)
KR (1)	KR101443056B1 (fr)
CN (2)	CN101511838A (fr)
AR (1)	AR062745A1 (fr)
AU (1)	AU2007296592B8 (fr)
BR (1)	BRPI0716781A2 (fr)
CA (1)	CA2663175C (fr)
CL (1)	CL2007002617A1 (fr)
CO (1)	CO6160236A2 (fr)
CR (1)	CR10636A (fr)
DK (1)	DK2094708T3 (fr)
ES (1)	ES2437318T3 (fr)
GT (1)	GT200900055A (fr)
HN (1)	HN2009000455A (fr)
IL (1)	IL197381A (fr)
MA (1)	MA30781B1 (fr)
MX (1)	MX2009002616A (fr)
MY (1)	MY148107A (fr)
NI (1)	NI200900021A (fr)
NO (1)	NO20091265L (fr)
NZ (1)	NZ575496A (fr)
PE (1)	PE20081372A1 (fr)
PT (1)	PT2094708E (fr)
RU (1)	RU2440352C2 (fr)
TN (2)	TN2009000049A1 (fr)
TW (1)	TWI399379B (fr)
UA (1)	UA94622C2 (fr)
UY (1)	UY30584A1 (fr)
WO (1)	WO2008033798A2 (fr)
ZA (1)	ZA200901073B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2009218607B2 (en)	2008-02-25	2014-02-13	F. Hoffmann-La Roche Ag	Pyrrolopyrazine kinase inhibitors
JP5485178B2 (ja)	2008-02-25	2014-05-07	エフ．ホフマン−ラロシュアーゲー	ピロロピラジンキナーゼ阻害剤
CA2713718A1 (fr)	2008-02-25	2009-09-03	F. Hoffmann-La Roche Ag	Inhibiteurs de kinase pyrrolopyrazine
CN101952294B (zh)	2008-02-25	2014-11-26	霍夫曼-拉罗奇有限公司	吡咯并吡嗪激酶抑制剂
CN101952295B (zh)	2008-02-25	2013-11-20	霍夫曼-拉罗奇有限公司	吡咯并吡嗪激酶抑制剂
KR20110009084A (ko) *	2008-03-10	2011-01-27	사노피-아벤티스	눈-관련된 장애의 치료방법
FR2929851B1 (fr)	2008-04-09	2012-11-30	Centre Nat Rech Scient	Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
PA8851701A1 (es)	2008-12-03	2010-07-27	Sanofi Aventis	Tratamiento para la glomerulonefritis
EP2373655A1 (fr)	2008-12-04	2011-10-12	Sanofi	Formes cristallines
TW201034675A (en) *	2008-12-18	2010-10-01	Sanofi Aventis	Method for treating macular degeneration
US20110112101A1 (en) *	2009-03-05	2011-05-12	Sanofi-Aventis	Treatment for ocular-related disorders
AR075869A1 (es) *	2009-03-19	2011-05-04	Sanofi Aventis	Sintesis de azaindoles
ME02186B (me)	2009-12-23	2016-02-20	Takeda Pharmaceuticals Co	Fuzionisani heteroaromatski pirolidinoni kao syk inhibitori
US8481541B2 (en)	2010-03-22	2013-07-09	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
US8518945B2 (en)	2010-03-22	2013-08-27	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
JP2013526558A (ja)	2010-05-20	2013-06-24	エフ．ホフマン−ラロシュアーゲー	Ｓｙｋ及びｊａｋ阻害剤としてのピロロピラジン誘導体
KR20130083386A (ko) *	2010-05-20	2013-07-22	에프. 호프만-라 로슈 아게	피롤로[2,3-ｂ]피라진-7-카복스아마이드 유도체 및 ＪＡＫ 및 ＳＹＫ 억제제로서의 그의 용도
EP2441755A1 (fr)	2010-09-30	2012-04-18	Almirall, S.A.	Dérivés de pyridine et isoquinoline comme inhibiteurs des kinases Syk et JAK
EP2489663A1 (fr)	2011-02-16	2012-08-22	Almirall, S.A.	Composés en tant qu'inhibiteurs de la syk kinase
JP6026525B2 (ja)	2011-06-22	2016-11-16	武田薬品工業株式会社	置換６−アザ−イソインドリン−１−オン誘導体
JP6404215B2 (ja) *	2012-08-21	2018-10-10	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	Ｓｙｋ阻害剤としてのピロロ［２，３−ｂ］ピラジン
EP3027601B1 (fr) *	2013-07-31	2017-10-25	Gilead Sciences, Inc.	Inhibiteurs syk
MX2021009863A (es)	2019-03-21	2021-11-12	Onxeo	Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
KR20220098759A (ko)	2019-11-08	2022-07-12	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (fr)	2020-01-22	2021-07-29	Onxeo	Nouvelle molécule dbait et son utilisation
CN116969927B (zh) *	2023-06-07	2024-03-19	中南民族大学	一种从荜茇中提取分离的化合物及该化合物在制备抗炎药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1141949A (en) *	1966-02-23	1969-02-05	Sterling Drug Inc	7-azaindole derivatives
US3992392A (en) *	1973-04-27	1976-11-16	The Ohio State University Research Foundation	Synthesis of indoles from anilines and intermediates therein
SE9100920D0 (sv)	1991-03-27	1991-03-27	Astra Ab	New active compounds
GB9226855D0 (en) *	1992-12-23	1993-02-17	Erba Carlo Spa	Vinylene-azaindole derivatives and process for their preparation
US6075037A (en)	1994-06-09	2000-06-13	Smithkline Beecham Corporation	Endothelin receptor antagonists
FR2732969B1 (fr)	1995-04-14	1997-05-16	Adir	Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK0948495T3 (da)	1996-11-19	2004-06-01	Amgen Inc	Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler
US6312835B1 (en)	1997-02-13	2001-11-06	Queen's University At Kingston	Luminescent compounds and methods of making and using same
HUP0001507A3 (en)	1997-03-19	2002-01-28	Abbott Gmbh & Co Kg	Pyrrolo [2,3-d] pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
WO1998047899A1 (fr)	1997-04-24	1998-10-29	Ortho-Mcneil Corporation, Inc.	Pyrrolopyridines substituees utilisees dans le traitement des maladies inflammatoires
EA200000098A1 (ru)	1997-08-05	2000-08-28	Пфайзер Продактс Инк.	4-АМИНОПИРРОЛ(3,2-d)ПИРИМИДИНЫ В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА НЕЙРОПЕПТИДА Y
JP3579350B2 (ja)	1997-10-20	2004-10-20	エフ．ホフマン−ラロシュアーゲー	二環式キナーゼ阻害剤
CA2322487C (fr)	1998-03-06	2010-07-20	Metabasis Therapeutics, Inc.	Nouveaux promedicaments pour composes contenant du phosphore
WO1999051233A1 (fr)	1998-04-02	1999-10-14	Merck & Co., Inc.	Antagonistes de l'hormone liberant la gonadotropine (gnrh)
CA2326140A1 (fr)	1998-04-02	1999-10-14	Merck & Co., Inc.	Antagonistes de l'hormone liberant la gonadotropine (gnrh)
JP4549534B2 (ja)	1998-05-26	2010-09-22	中外製薬株式会社	複素環を有するインドール誘導体及びモノ又はジアザインドール誘導体
CZ2001959A3 (cs)	1998-09-18	2001-12-12	Basf Aktiengesellschaft	4-Aminopyrrolopyrimidiny jako inhibitory kinasy
PE20010306A1 (es)	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
EA005212B1 (ru)	1999-12-24	2004-12-30	Авентис Фарма Лимитед	Азаиндолы
GB9930698D0 (en) *	1999-12-24	2000-02-16	Rhone Poulenc Rorer Ltd	Chemical compounds
US6770666B2 (en) *	1999-12-27	2004-08-03	Japan Tobacco Inc.	Fused-ring compounds and use thereof as drugs
YU54202A (sh)	2000-01-18	2006-01-16	Agouron Pharmaceuticals Inc.	Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
DE10009000A1 (de) *	2000-02-25	2001-08-30	Basf Ag	Verfahren zur Herstellung substituierter Indole
AU2001247589A1 (en) *	2000-03-20	2001-10-03	Axys Pharmaceuticals, Inc.	Non-amidine containing protease inhibitors
JP2001302667A (ja) *	2000-04-28	2001-10-31	Bayer Ag	イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
AU2001261189A1 (en) *	2000-05-03	2001-11-12	Tularik, Inc.	Pyrazole antimicrobial agents
AU2001259707A1 (en)	2000-06-14	2001-12-24	Warner Lambert Company	6,5-fused bicyclic heterocycles
JP2004510762A (ja)	2000-10-02	2004-04-08	メルク　エンド　カムパニー　インコーポレーテッド	プレニル−蛋白質トランスフェラーゼの阻害剤
GB0115109D0 (en) *	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
WO2003000690A1 (fr)	2001-06-25	2003-01-03	Aventis Pharmaceuticals Inc.	Synthese de composes heterocycliques faisant appel a une technologie micro-onde
AR035543A1 (es)	2001-06-26	2004-06-16	Japan Tobacco Inc	Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
AU2002334217B2 (en)	2001-10-26	2008-07-03	Aventis Pharmaceuticals Inc.	Benzimidazoles and analogues and their use as protein kinases inhibitors
US20040082365A1 (en) *	2002-07-18	2004-04-29	Celerica Ltd	Digitization and transmitting cellular RF signals by several light wavelengths
EP1388541A1 (fr)	2002-08-09	2004-02-11	Centre National De La Recherche Scientifique (Cnrs)	Pyrrolopyrazines utilisées comme inhibiteurs de kinases
WO2005014543A1 (fr)	2003-08-06	2005-02-17	Japan Tobacco Inc.	Compose a cycle condense utilise comme inhibiteur de la polymerase du vhc
MX2007001126A (es) *	2004-07-27	2007-09-25	Sgx Pharmaceuticals Inc	Moduladores de heterociclo cinasa de anillo fusionado.
GB0420719D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
FR2876582B1 (fr)	2004-10-15	2007-01-05	Centre Nat Rech Scient Cnrse	Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
EP1809279B1 (fr)	2004-11-08	2013-05-29	Baxter International Inc.	Compositions particulaires d'inhibiteurs de la tubuline
EP1814882A1 (fr) *	2004-11-22	2007-08-08	Vertex Pharmaceuticals Incorporated	Pyrrolopyrazines et pyrazolopyrazines convenant inhibiteurs de proteines-kinases
US20110112101A1 (en) *	2009-03-05	2011-05-12	Sanofi-Aventis	Treatment for ocular-related disorders

2007
- 2007-09-10 CL CL200702617A patent/CL2007002617A1/es unknown
- 2007-09-11 UY UY30584A patent/UY30584A1/es not_active Application Discontinuation
- 2007-09-11 NZ NZ575496A patent/NZ575496A/en not_active IP Right Cessation
- 2007-09-11 WO PCT/US2007/078103 patent/WO2008033798A2/fr active Search and Examination
- 2007-09-11 EP EP07842207.8A patent/EP2094708B1/fr active Active
- 2007-09-11 CA CA2663175A patent/CA2663175C/fr not_active Expired - Fee Related
- 2007-09-11 MX MX2009002616A patent/MX2009002616A/es active IP Right Grant
- 2007-09-11 ES ES07842207.8T patent/ES2437318T3/es active Active
- 2007-09-11 BR BRPI0716781-4A2A patent/BRPI0716781A2/pt not_active IP Right Cessation
- 2007-09-11 PE PE2007001220A patent/PE20081372A1/es not_active Application Discontinuation
- 2007-09-11 KR KR1020097005040A patent/KR101443056B1/ko not_active Expired - Fee Related
- 2007-09-11 AR ARP070104013A patent/AR062745A1/es not_active Application Discontinuation
- 2007-09-11 MY MYPI20090720A patent/MY148107A/en unknown
- 2007-09-11 CN CNA2007800336608A patent/CN101511838A/zh active Pending
- 2007-09-11 DK DK07842207.8T patent/DK2094708T3/da active
- 2007-09-11 AU AU2007296592A patent/AU2007296592B8/en not_active Ceased
- 2007-09-11 RU RU2009113615/04A patent/RU2440352C2/ru not_active IP Right Cessation
- 2007-09-11 TW TW096133786A patent/TWI399379B/zh not_active IP Right Cessation
- 2007-09-11 CN CN201310652393.XA patent/CN103804383A/zh active Pending
- 2007-09-11 JP JP2009538434A patent/JP5161237B2/ja not_active Expired - Fee Related
- 2007-09-11 PT PT78422078T patent/PT2094708E/pt unknown
- 2007-11-09 UA UAA200903417A patent/UA94622C2/ru unknown
2009
- 2009-02-16 ZA ZA2009/01073A patent/ZA200901073B/en unknown
- 2009-02-17 TN TN2009000049A patent/TN2009000049A1/fr unknown
- 2009-02-17 NI NI200900021A patent/NI200900021A/es unknown
- 2009-02-17 TN TN2009000050A patent/TN2009000050A1/fr unknown
- 2009-02-25 CR CR10636A patent/CR10636A/es not_active Application Discontinuation
- 2009-03-03 IL IL197381A patent/IL197381A/en not_active IP Right Cessation
- 2009-03-10 GT GT200900055A patent/GT200900055A/es unknown
- 2009-03-10 US US12/401,254 patent/US8658649B2/en not_active Expired - Fee Related
- 2009-03-10 HN HN2009000455A patent/HN2009000455A/es unknown
- 2009-03-11 CO CO09025278A patent/CO6160236A2/es unknown
- 2009-03-26 NO NO20091265A patent/NO20091265L/no not_active Application Discontinuation
- 2009-04-06 MA MA31765A patent/MA30781B1/fr unknown
2014
- 2014-01-28 US US14/166,396 patent/US20140142110A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2008033798A2 (fr)	2008-03-20
AU2007296592B2 (en)	2011-12-15
CN103804383A (zh)	2014-05-21
NO20091265L (no)	2009-04-03
KR20090063214A (ko)	2009-06-17
HN2009000455A (es)	2012-02-13
AU2007296592B8 (en)	2012-01-12
MX2009002616A (es)	2009-03-24
CN101511838A (zh)	2009-08-19
NI200900021A (es)	2010-01-29
MY148107A (en)	2013-02-28
DK2094708T3 (da)	2014-01-27
AU2007296592A1 (en)	2008-03-20
UY30584A1 (es)	2008-05-02
KR101443056B1 (ko)	2014-09-22
EP2094708A2 (fr)	2009-09-02
JP2010502767A (ja)	2010-01-28
TWI399379B (zh)	2013-06-21
AR062745A1 (es)	2008-12-03
BRPI0716781A2 (pt)	2014-11-18
ZA200901073B (en)	2009-12-30
IL197381A0 (en)	2009-12-24
TN2009000050A1 (en)	2010-08-19
PE20081372A1 (es)	2008-11-27
CL2007002617A1 (es)	2008-05-16
US8658649B2 (en)	2014-02-25
ES2437318T3 (es)	2014-01-10
MA30781B1 (fr)	2009-10-01
CO6160236A2 (es)	2010-05-20
EP2094708B1 (fr)	2013-10-23
CA2663175C (fr)	2012-03-13
US20140142110A1 (en)	2014-05-22
US20100035884A1 (en)	2010-02-11
UA94622C2 (en)	2011-05-25
JP5161237B2 (ja)	2013-03-13
TW200829590A (en)	2008-07-16
CR10636A (es)	2009-03-20
PT2094708E (pt)	2014-01-07
RU2440352C2 (ru)	2012-01-20
WO2008033798A3 (fr)	2008-05-15
NZ575496A (en)	2011-09-30
RU2009113615A (ru)	2010-10-20
IL197381A (en)	2013-11-28
GT200900055A (es)	2010-07-28
CA2663175A1 (fr)	2008-03-20

Publication	Publication Date	Title
TN2009000049A1 (en)	2010-08-19	A pyrrolopyrazin as syk-kinase inhibitor
MY149512A (en)	2013-09-13	Pyrazolylaminopyridine derivatives useful as kinase inhibitors
PT1940839E (pt)	2013-10-10	Inibidores de piridopirimidinona pi3k alfa
WO2006123113A3 (fr)	2007-01-04	Composes chimiques
MX2009000884A (es)	2009-06-05	Derivados de piridizinona.
PH12012502057A1 (en)	2015-09-14	Compounds for inhibiting mitotic progression
MX2009003834A (es)	2009-04-22	Derivados de pirrolidina como inhibidores de iap.
SG179418A1 (en)	2012-04-27	Inhibitors of the hedgehog pathway
NZ585460A (en)	2013-02-22	Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2009016460A8 (fr)	2009-10-15	Composés pyrazoles
MX2010004263A (es)	2010-05-03	Inhibidores de quinasa c-fms.
MY151003A (en)	2014-03-31	Stable pharmaceutical composition comprising a pyrimidine-sulfamide
EA201200049A1 (ru)	2012-08-30	1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
WO2008022286A3 (fr)	2008-04-17	petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
MX2009011579A (es)	2009-11-11	Pirimidinonas como moduladores de caseina cinasa ii (ck2).
MX2009005691A (es)	2009-08-07	Inhibidores de la enzima de diacilglicerol o-acilotransferasa tipo i.
TNSN08191A1 (en)	2009-10-30	Kinase inhibitors
TN2010000038A1 (en)	2011-09-26	Organic compounds
PH12013500695A1 (en)	2017-08-09	Pharmaceutical compositions containing a dgat1 inhibitor
MY147188A (en)	2012-11-14	Substituted imidazole compounds as ksp inhibitors
UA97821C2 (en)	2012-03-26	Cyclized derivatives as eg-5 inhibitors
EA200900631A1 (ru)	2009-12-30	Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
MX2008016358A (es)	2009-01-16	Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.
TNSN08369A1 (en)	2009-12-29	Benzimidazole derivatives
UA96969C2 (en)	2011-12-26	Acylaminopyrazoles as fgfr inhibitors